Jump to content

Levobetaxolol

From Wikipedia, the free encyclopedia
(Redirected from Betaxon)
Levobetaxolol
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
topical (ophthalmic)
ATC code
  • none
Pharmacokinetic data
Elimination half-life20 hours
Identifiers
  • (S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H29NO3
Molar mass307.434 g·mol−1
3D model (JSmol)
  • O(CCc1ccc(OC[C@@H](O)CNC(C)C)cc1)CC2CC2
  • InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1 checkY
  • Key:NWIUTZDMDHAVTP-KRWDZBQOSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Indications

[edit]

It is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension.[1]

Effect

[edit]

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

[edit]

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated with bradycardia and hypertension.[citation needed]

History

[edit]

Levobetaxolol was developed in the 1980s.[1] It was FDA approved in 2000.[2]

References

[edit]
  1. ^ a b c Quaranta L, Turano R, Pizzolante T (June 2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology. 1 (2): 93–7. PMC 2704505. PMID 19668496.
  2. ^ "Betaxon New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 11 April 2019.